In 2006, Beasley et al. [24] reported that the protein levels of DPYSL2 correlated significantly with antipsychotic exposure and, in 2013, Pickering et al. [25] reported that chronic treatment of rat with phencyclidine, a drug that mimic schizophrenia symptoms, downregulates DPYSL2 and upregulates DPYSL3 levels in the medial prefrontal cortex. Here, DPYSL2 is linked to schizophrenia.